TIMI 15B evaluated the pharmacodynamic response, safety and pharmacokinetics of the GP IIb/IIIa inhibitor RPR 109891 given intravenously followed by oral administration for the treatment of patients with acute coronary syndromes.
TIMI 15B evaluated the pharmacodynamic response, safety and pharmacokinetics of the GP IIb/IIIa inhibitor RPR 109891 given intravenously followed by oral administration for the treatment of patients with acute coronary syndromes.